LifeStance Health Group Inc. Common Stock vs Medpace Holdings Inc — how do they compare? LifeStance Health Group Inc. Common Stock trades at $12.42 (market cap $4.58B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 3.7× LifeStance Health Group Inc. Common Stock's market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 2,356,698). Which is the better fit depends on your goals — on Pluang, investors hold LifeStance Health Group Inc. Common Stock for 1 Days and Medpace Holdings Inc for 14 Days on average.
| LFST | MEDP | |
|---|---|---|
Market Cap | $4.58B | $16.82B |
Volume | 2,356,698 | 223,093 |
Sector | Health | Health |
52-Week High | $13.38 | $630.19 |
52-Week Low | $4.81 | $393.42 |
Typical Hold Time | 1 Days | 14 Days |
Enterprise Value | $4.82B | $16.44B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
LifeStance Health provides outpatient mental healthcare, including therapy, psychiatry, and medication management services.
Read more on LFST →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →